Posted by Michael Wonder on 21 May 2017
Amgen submits biologics license application to the FDA for erenumab
18 May 2017 - Erenumab is an investigative treatment specifically designed to prevent migraine only molecule in late-stage development to directly target the calcitonin gene-related peptide receptor.
Amgen today announced the submission of a biologics license application to the U.S. FDA for erenumab to prevent migraine. Erenumab is specifically designed to prevent migraine by blocking the calcitonin gene-related peptide receptor.
The application includes data from pivotal studies in patients with episodic and chronic migraine.
